Use of Myo-inositol for Ovulation Induction in Patients with Polycystic Ovary Syndrome

Title: Use of Myo-inositol for Ovulation Induction in Patients with Polycystic Ovary Syndrome

Authors: Dr Tabassum Ahmed, Dr Renu Rohtagi, Dr Punit Hans

DOI: https://dx.doi.org/10.18535/jmscr/v5i6.66

Abstract

Objectives: Administration of isoform of inositol (myo-inositol) belonging to Vitamin B complex would improve insulin receptor activity, in restoring normal ovulatory function.

Method:25 PCOS patients of child bearing age were enrolled in the study. Only ovulatory disorders due to PCOS were included in the study. All other factors of infertility were excluded.

Myo-inositol combined with folic acid 2 gram twice daily was administered continuously for a period of six months Ovulation was assessed by ultrasound scan and hormonal profile and number of spontaneous menstrual cycle eventual pregnancies were assessed

Result: 20 out of 25 (80%) patients restored at least one spontaneous menstrual cycle. During treatment of whom 16 (64%)had normal ovulatory activity during follow up period.A total of 12 singleton pregnancy (48%) occurred. 2 pregnancies terminated in spontaneous abortion.

Conclusion: Myo-inositolis a simple and safe treatment for ovulation induction and subsequent pregnancy. The therapy did not cause multiple pregnancy.

Keywords: PCOS, Ovulation induction, Myo-inositol

References

1. 1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.

2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.

3. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.

4. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab2006;91:22-24.

5. Larner J. Multiple pathways in insulin signaling - fitting the covalent and allosteric puzzle pieces together. Endocr J 1994; 2:167-171.

6. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro- inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300-305.

7. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effect of D-chiro-inositol in lean women with the polycystic ovary syndrome. EndocrPract2002;8:417-423.

8. Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Appl Environ Microbiol 2006;72:1310-1315.

9. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentra¬tions of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reprod2002;17:1591-1596.

10. Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effect of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Human Reprod 2003;18: 408-416.

11. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005;84: 611-616.

12. Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online 2004;9:614-619.

13. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004;8:440-447.

14. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005;6:1012- 1022.

15. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, et al.; Cooperative Multicenter Repro-ductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-566.

16. Pesant MH, Baillargeon JP. Ovulation induction in polycystic ovary syndrome - how do metformin and clomifene citrate compare? Nat Clin Pract Endocr Metab2007;3:512-513.

17. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. B Med J 2003;327:951-957.

Call For Paper Volume 12 Issue 10 November 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 11 November 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 11 November 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search